The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on CVS Health (CVS – Research Report), with a price target of ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

CVS Health had a challenging 2024 and it may take ... regulatory headwinds with challenges against PBMs. Fitch sees CVS Caremark, the company's PBM, as a "key engine of profitability" unless ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

CVS Caremark, Express Scripts ... based on a subset of medications that represent less than 2% of what our health plans spend on medications in a year.” Express Scripts sued the FTC in September ...

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, ...